<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21935" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Foscarnet</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garikapati</surname>
            <given-names>Sriram</given-names>
          </name>
          <aff>St. George's University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Minhthao</given-names>
          </name>
          <aff>University Hospitals Richmond and Bedford Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sriram Garikapati declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Minhthao Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21935.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Foscarnet is an antiviral agent used to treat cytomegalovirus (CMV), herpes simplex virus (HSV), and varicella-zoster virus (VZV) infections, particularly in immunocompromised individuals. Foscarnet&#x000a0;is typically reserved for&#x000a0;viral strains for which first-line treatments may be less effective. This activity examines the drug's mechanism of action, contraindications, adverse effects, and the FDA's boxed warnings. Pharmacokinetic properties and drug interactions will also be reviewed, providing essential knowledge for adjusting dosages to minimize adverse effects.</p>
        <p>Foscarnet requires careful management due to its nephrotoxic potential and electrolyte imbalances, among other risks. Understanding the role of an interprofessional healthcare team in monitoring and managing these adverse effects is critical for ensuring patient safety. A strong focus on adherence to evidence-based treatment protocols enhances the antiviral effectiveness of foscarnet. This activity highlights the importance of optimizing treatment regimens to improve patient outcomes with complex viral infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for foscarnet therapy.</p></list-item><list-item><p>Assess the most common adverse events associated with foscarnet administration.</p></list-item><list-item><p>Determine the importance of monitoring patients on foscarnet therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from foscarnet therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21935&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21935">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21935.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Foscarnet is an FDA-approved antiviral&#x000a0;therapy&#x000a0;used to treat cytomegalovirus (CMV) and CMV-associated ophthalmic retinitis in individuals diagnosed with AIDS and who are unable to tolerate ganciclovir. The drug may also be prescribed as salvage therapy for&#x000a0;patients&#x000a0;with drug-resistant&#x000a0;CMV&#x000a0;who have failed ganciclovir therapy.&#x000a0;Foscarnet&#x000a0;has also been approved as a treatment option in immunocompromised patients with mucocutaneous herpes simplex virus (HSV) who&#x000a0;exhibit resistance to acyclovir, the gold standard therapy for HSV.<xref ref-type="bibr" rid="article-21935.r1">[1]</xref><xref ref-type="bibr" rid="article-21935.r2">[2]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Foscarnet also has off-label use in certain instances, such as gastrointestinal diseases including esophagitis or colitis, outer retinal necrosis, allogeneic stem cell transplant, varicella zoster virus (VZV) treatment, and even in the prevention of CMV infection itself.<xref ref-type="bibr" rid="article-21935.r3">[3]</xref><xref ref-type="bibr" rid="article-21935.r4">[4]</xref><xref ref-type="bibr" rid="article-21935.r1">[1]</xref>&#x000a0;Foscarnet is often&#x000a0;administered as monotherapy or&#x000a0;in combination&#x000a0;with agents such as ganciclovir for CMV and acyclovir for HSV. When ganciclovir alone is ineffective, clinicians will often combine it with foscarnet. If&#x000a0;ganciclovir&#x000a0;therapy causes&#x000a0;strong adverse effects in a patient, foscarnet is administered&#x000a0;instead.<xref ref-type="bibr" rid="article-21935.r5">[5]</xref>&#x000a0;While foscarnet is often indicated for the above-mentioned viral infections in immunocompromised patients, it has no use in treating HIV because it does not have antiretroviral properties. Preemptive treatment with foscarnet for early human herpesvirus 6 (HHV-6) reactivation in allogeneic stem cell transplant patients effectively prevents complications, with no cases of encephalitis or pneumonitis. The treatment&#x000a0;results&#x000a0;in undetectable viral loads and minimal adverse effects, demonstrating a safe, effective strategy.<xref ref-type="bibr" rid="article-21935.r6">[6]</xref>&#x000a0;The Infectious Diseases Society of America (IDSA) acknowledges the potential use of foscarnet as an option for outpatient parenteral antibiotic therapy (OPAT) in select patients.<xref ref-type="bibr" rid="article-21935.r7">[7]</xref></p>
      </sec>
      <sec id="article-21935.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Foscarnet is an analog of pyrophosphate, a phosphorous oxyanion found in the DNA molecule. This analog acts like the pyrophosphate molecule by binding selectively and reversibly to the binding site on the DNA polymerase enzyme of the virus and inhibiting the DNA chain from elongating further. The DNA polymerase enzyme cleaves the pyrophosphate molecule from the DNA chain to add further nucleotides to the growing chain. Foscarnet binding inhibits this cleaving process. While foscarnet has selectivity for the viral DNA polymerase, it can also inhibit human DNA polymerase in much larger drug concentrations. However, such high concentrations are seldom necessary to treat these viral pathogens.<xref ref-type="bibr" rid="article-21935.r3">[3]</xref>&#x000a0;Mutations in the <italic toggle="yes">UL54</italic> gene can cause foscarnet resistance.<xref ref-type="bibr" rid="article-21935.r8">[8]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Foscarnet is administered as an intravenous infusion. At steady state, foscarnet's maximum plasma concentration (Cmax) is 589 &#x000b1; 192 &#x000b5;M.</p>
        <p><bold>Distribution:</bold>&#x000a0;The volume of distribution for foscarnet ranges from 0.41 to 0.52 L/kg. Approximately 14% to 17% of foscarnet is protein-bound. Additionally, foscarnet exhibits a cerebrospinal fluid (CSF) to plasma ratio of 0.69 for the 60 mg/kg dosage every 8 hours and 0.66 for the 90 mg/kg dosage every 12 hours.</p>
        <p><bold>Metabolism:</bold> Foscarnet is excreted in the urine and&#x000a0;undergoes&#x000a0;negligible hepatic metabolism.<xref ref-type="bibr" rid="article-21935.r9">[9]</xref></p>
        <p><bold>Excretion:</bold> Foscarnet's plasma half-life is approximately 4.0 hours for the 60 mg/kg regimen administered every 8 hours and about 3.3 hours for the 90 mg/kg regimen administered every 12 hours. Foscarnet&#x000a0;exhibits a&#x000a0;prolonged urinary excretion half-life of 87.5 hours, which may be attributed to its accumulation in bone.</p>
      </sec>
      <sec id="article-21935.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Foscarnet&#x000a0;exhibits poor bioavailability when orally administered,&#x000a0;possibly due to the poor metabolism of the drug and its inclination to deposit within bone and cartilage.<xref ref-type="bibr" rid="article-21935.r3">[3]</xref>&#x000a0;As a result, foscarnet is most commonly administered intravenously. The dosing and rate of administration are determined based on the patient's&#x000a0;age and weight and the specific viral infection (ie, CMV versus HSV or VZV). While the IV route is the most commonly used, foscarnet may administered via the intravitreal route by experienced clinicians as a treatment for viral ophthalmic complications.<xref ref-type="bibr" rid="article-21935.r10">[10]</xref> Foscarnet should not be administered by rapid or bolus intravenous injection; instead, it should be delivered using an infusion pump.</p>
        <p>For peripheral line administration, dilute foscarnet injection to the appropriate concentration using 5% dextrose in water (D5W) or normal saline (NS).</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Specific dosing regimens based on indication are listed below.</p>
        <p>
<bold>AIDS-associated CMV retinitis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Foscarnet is not considered a first-line treatment for this condition.</p>
          </list-item>
          <list-item>
            <p>Induction: 90 mg/kg/dose IV every 12 hours for&#x000a0;2 to&#x000a0;3 weeks, or 60 mg/kg/dose IV every 8 hours for 2 to 3 weeks.</p>
          </list-item>
          <list-item>
            <p>Maintenance: 90 mg/kg/dose IV every 24 hours, or 120 mg/kg/dose IV every 24 hours.</p>
          </list-item>
        </list>
        <p>
<bold>Acyclovir-resistant mucocutaneous HSV infection:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>40 mg/kg/dose IV every 8 to 12 hours until healed; alternately, apply 1% cream&#x000a0;5 times daily until healed (requires pharmacy compounding)</p>
          </list-item>
          <list-item>
            <p>Immunocompromised patients must maintain adequate hydration before and during IV treatment.<xref ref-type="bibr" rid="article-21935.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ganciclovir-resistant CMV (off-label):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Induction: 90 mg/kg/dose IV for a minimum of 2 weeks; alternately, 60 mg/kg/dose IV every 8 hours for a minimum of 2 weeks.</p>
          </list-item>
          <list-item>
            <p>Maintenance:&#x000a0;90 mg/kg/dose IV every 24 hours, or 120 mg/kg/dose IV every 24 hours.<xref ref-type="bibr" rid="article-21935.r12">[12]</xref><xref ref-type="bibr" rid="article-21935.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Immunocompromised patients must maintain adequate hydration before and during IV treatment.</p>
          </list-item>
        </list>
        <p>
<bold>Acyclovir-resistant varicella (off-label):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>90 mg/kg/dose IV every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Immunocompromised patients must maintain adequate hydration before and during IV treatment.</p>
          </list-item>
        </list>
        <p>
<bold>Acyclovir-resistant herpes zoster (off-label):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For adults with CMV infection and retinitis,&#x000a0;foscarnet is commonly administered at about 1 mg/kg/min.<xref ref-type="bibr" rid="article-21935.r12">[12]</xref><xref ref-type="bibr" rid="article-21935.r13">[13]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>For all patients, the therapy duration depends on the patient's&#x000a0;immune status and the progress of the lesions.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Intravenous foscarnet can cause mild-to-moderate serum alanine aminotransferase (ALT) elevations, particularly in patients with multiorgan disease. These asymptomatic elevations often resolve with continued therapy. Rare cases of cholestatic liver injury have been reported. Rapid renal excretion and minimal hepatic metabolism likely account for its low hepatotoxicity.<xref ref-type="bibr" rid="article-21935.r9">[9]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;Significant dosing reductions are necessary in cases of renal compromise. Limited safety data exist for patients with serum creatinine &#x0003e;2.8 mg/dL or creatinine clearance &#x0003c;50 mL/min. Renal function must be monitored, with dose adjustments as needed. If creatinine clearance drops below 0.4 mL/min/kg, discontinue foscarnet, hydrate the patient, and monitor until renal function improves. Due to the lack of dosing guidelines, foscarnet is not recommended for patients undergoing hemodialysis. Clinicians should refer to package inserts and institutional protocols in such instances.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>There are no well-controlled studies of foscarnet in pregnant women, and animal studies do not always predict human response. Foscarnet should be&#x000a0;administered&#x000a0;during pregnancy only if indicated. In animal studies, foscarnet did not impair fertility or general reproductive performance, but a&#x000a0;mild increase in skeletal anomalies at subtherapeutic exposure levels was observed. These studies are insufficient to determine teratogenic risk at human exposure levels.&#x000a0;&#x000a0;</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Foscarnet excretion in human breast milk has not been determined, but studies in rats&#x000a0;revealed&#x000a0;higher concentrations in milk than in blood. Due to the risk of&#x000a0;severe adverse effects in nursing infants, a decision should be made to either discontinue the drug or breastfeed, considering the drug's importance to the mother. The CDC advises HIV-infected mothers not to breastfeed to prevent postnatal transmission of HIV.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Foscarnet's safety in pediatric patients has not been established.&#x000a0;The drug accumulates&#x000a0;in teeth and bones, with animal studies showing enamel defects. Although the effects on skeletal development are unclear, bone deposition is expected to be higher in children, making its use in pediatric populations a concern. While foscarnet is effective&#x000a0;for&#x000a0;treatment-resistant infections, its&#x000a0;associated nephrotoxicity necessitates careful renal monitoring. In pediatric patients, bone and tooth deposition risk requires a thorough evaluation, and treatment should only proceed if the therapeutic benefits outweigh these potential risks.<xref ref-type="bibr" rid="article-21935.r14">[14]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;Foscarnet has not been specifically studied in patients older than&#x000a0;65, but its use in older adults shows a similar adverse event profile across all ages.&#x000a0;Foscarnet is primarily excreted by the kidneys. Since renal function tends to decline with age, careful dosing is crucial to avoid toxicity in older individuals.</p>
      </sec>
      <sec id="article-21935.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>While there are multiple adverse effects associated with foscarnet administration, the most notable include nausea, electrolyte derangements, and nephrotoxicity. Of these&#x000a0;3 significant adverse effects, the reports of renal insufficiency are a relatively more common event in patients receiving this drug.&#x000a0;Any acute reduction in renal function is reversible; therefore, it is crucial to address it once identified. Foscarnet affects the renal tubular cells via direct cytotoxic mechanisms, and the degree of drug-induced toxicity directly correlates to the dosage administered.<xref ref-type="bibr" rid="article-21935.r15">[15]</xref>&#x000a0;Along with renal tubular damage, foscarnet can cause crystal nephropathy by deposition of crystals in the glomerular capillaries. These crystals are often a mix of sodium and calcium salts. The molecular aspects of foscarnet allow it to form complexes with these ions, leading to the deposition of these crystals in the glomerular network.<xref ref-type="bibr" rid="article-21935.r16">[16]</xref>&#x000a0;Foscarnet has been associated with reversible acute kidney injury (AKI), distal tubular acidosis, and arginine vasopressin resistance (AVP-R, formerly nephrogenic diabetes insipidus). The reported incidence of foscarnet-related nephrotoxicity varies widely, ranging from 20% to 66%. Early screening for crystalluria should be conducted in patients receiving foscarnet to identify potential risks and prevent the onset of acute kidney injury.<xref ref-type="bibr" rid="article-21935.r17">[17]</xref></p>
        <p>Due to these adverse renal effects, monitoring renal function while on foscarnet therapy is essential. Any elevation in plasma creatine observed within 2 weeks of initiating foscarnet&#x000a0;therapy&#x000a0;could be a sign of renal tubular injury; this often presents as acute tubular injury, with granular or muddy brown casts in the urine and a triphasic&#x000a0;sequence&#x000a0;involving an acute drop in GFR, followed by an elevation in GFR and then an eventual resolution of kidney function.<xref ref-type="bibr" rid="article-21935.r18">[18]</xref>&#x000a0;In some instances, foscarnet can also cause AVP-R.<xref ref-type="bibr" rid="article-21935.r19">[19]</xref></p>
        <p>Electrolyte derangement, another adverse effect of foscarnet, often presents with hypocalcemia and hypomagnesemia.<xref ref-type="bibr" rid="article-21935.r20">[20]</xref>&#x000a0;Hypocalcemia may be due to the formation of the foscarnet and calcium ion complex, or it may result from foscarnet-induced hypomagnesemia, which leads to both hypocalcemia (due to hypomagnesemia-induced hypoparathyroidism state) and hypokalemia (due to excess renal potassium wasting). Due to these possible electrolyte abnormalities, it is essential to&#x000a0;perform routine complete metabolic panels to prevent systemic adverse events such as cardiac arrhythmias and obtain a baseline EKG before initiation of treatment.</p>
        <p>Patient intolerance due to nausea and other gastrointestinal symptoms is a well-known and often reported adverse event of foscarnet and is a primary reason it is difficult to administer to patients. The administration of foscarnet usually involves concurrent IV and oral hydration to suppress nausea. Nausea can also be mitigated by providing the patient with antiemetics and slowing the drug infusion rate.<xref ref-type="bibr" rid="article-21935.r21">[21]</xref></p>
        <p>Less commonly reported adverse events due to foscarnet administration include seizures, genital ulcers, and anemia. Genital ulcers are more&#x000a0;common in males, possibly due to a topical toxic effect resulting from medication concentration in the urine. There are also reports of QT prolongation and torsades de pointes.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Concomitant administration of cidofovir with foscarnet should be avoided due to the increased risk of additive nephrotoxicity, which can lead to significant renal impairment. Similarly, pimozide and thioridazine should not be used together with foscarnet, as both can exacerbate QT prolongation, increasing the risk of serious cardiac arrhythmias.</p>
          </list-item>
          <list-item>
            <p>Pentamidine: Use with foscarnet requires caution due to the potential for hypocalcemia and renal impairment.</p>
          </list-item>
          <list-item>
            <p>Nephrotoxic drugs:&#x000a0;Avoid concurrent use of foscarnet with nephrotoxic agents such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, and tacrolimus unless the potential benefits outweigh the risks, as this combination may increase the likelihood of renal toxicity.</p>
          </list-item>
          <list-item>
            <p>Diuretics: Thiazide diuretics are recommended over loop diuretics when diuresis is necessary, as loop diuretics may interfere with the renal elimination of foscarnet and heighten toxicity risk.</p>
          </list-item>
          <list-item>
            <p>Ritonavir: Monitor for abnormal renal function when using foscarnet with ritonavir.</p>
          </list-item>
          <list-item>
            <p>QT-prolonging drugs: Avoid co-administration of Class IA and Class III antiarrhythmics such as quinidine, procainamide, dofetilide, amiodarone, and sotalol with foscarnet due to an increased risk of QT prolongation and torsades de pointes.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21935.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the product labeling,&#x000a0;foscarnet is contraindicated&#x000a0;for patients with severe hypersensitivity reactions such as angioedema or a history of anaphylactic reactions to it. Foscarnet is relatively contraindicated for patients with underlying diseases&#x000a0;that increase the effect of the adverse reaction profile of the drug. With the health care provider&#x02019;s medical discretion, the drug is&#x000a0;administered with extreme caution or not at all in patients who have abnormal EKG readings due to chronic cardiac problems, chronic kidney disease, underlying electrolyte abnormalities (which have to be corrected before administering foscarnet) or seizure disorders.</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Nephrotoxicity is the primary concern with foscarnet administration.&#x000a0;Clinicians must&#x000a0;monitor serum creatinine levels frequently, adjust doses based on changes in renal function, and ensure adequate hydration during foscarnet therapy. Foscarnet-induced alterations in plasma minerals and electrolytes have been linked to seizure activity. Therefore, patients should be closely monitored for&#x000a0;these changes and their potential consequences. Mineral and electrolyte supplementation may be necessary. Foscarnet is indicated solely for immunocompromised patients with CMV retinitis and mucocutaneous infections caused by acyclovir-resistant&#x000a0;HSV. A recent study revealed an increased risk of seizures, nephrotoxicity, and electrolyte imbalance associated with foscarnet.<xref ref-type="bibr" rid="article-21935.r22">[22]</xref></p>
      </sec>
      <sec id="article-21935.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Given the&#x000a0;various&#x000a0;adverse effects associated with foscarnet administration, it is essential to monitor specific parameters. The&#x000a0;3 main monitoring components are 24-hour creatinine clearance, ECG, and baseline electrolyte measurements. Clinicians must obtain a baseline complete blood count to monitor hematocrit, hemoglobin, and white blood cell counts.&#x000a0;As a part of&#x000a0;maintenance therapy,&#x000a0;providers should evaluate&#x000a0;calcium, potassium, sodium, magnesium, and phosphorus levels weekly.&#x000a0;Foscarnet can cause hypokalemic hyperchloremic metabolic acidosis.<xref ref-type="bibr" rid="article-21935.r23">[23]</xref>&#x000a0;Various symptoms, such as muscle twitching and anxiety, warrant&#x000a0;more frequent&#x000a0;monitoring of electrolyte levels.<xref ref-type="bibr" rid="article-21935.r24">[24]</xref>&#x000a0;Monitoring calcium ion status is especially useful for detecting renal dysfunction during the early period of foscarnet administration.<xref ref-type="bibr" rid="article-21935.r25">[25]</xref>&#x000a0;</p>
        <p>The frequency of monitoring may vary depending on the patient's specific medical history and treatment course.&#x000a0;Clinicians should also&#x000a0;check the patient's hydration status before initiating the infusion of foscarnet to avoid symptoms like nausea. Lastly, the patient and provider should monitor for signs of hypersensitivity reactions with foscarnet to prevent complications. Dosing the drug appropriately, depending on the patient's medical history and current drug tolerance status, is crucial.</p>
      </sec>
      <sec id="article-21935.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Clinical features of foscarnet toxicity include seizures, nephrotoxicity, paresthesias, and electrolyte imbalances. Severe overdose may result in coma and fatal respiratory or cardiac arrest.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>To prevent irreversible damage, the patient should have frequent bloodwork and constant monitoring for renal impairment, electrolyte derangement, and seizures in overdose situations.&#x000a0;The risk of nephrotoxicity can be mitigated by concurrent administration of 0.9% normal saline (about 0.5 to 1.0 L) or dextrose 5% water solution. While a history of chronic renal&#x000a0;disease can increase the risk of foscarnet toxicity, it is also important to withhold the administration of other potentially nephrotoxic drugs such as ACE&#x000a0;inhibitors, angiotensin II receptor blockers, amphotericin B, vancomycin, or aminoglycosides to reduce the risk of additional renal damage.<xref ref-type="bibr" rid="article-21935.r26">[26]</xref><xref ref-type="bibr" rid="article-21935.r27">[27]</xref>&#x000a0;While there is no particular antidote for foscarnet overdose, it can be prevented&#x000a0;through adequate prophylactic hydration or urgent hemodialysis to decrease drug plasma levels.</p>
      </sec>
      <sec id="article-21935.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing the administration of foscarnet to immunocompromised individuals infected with HSV, CMV, or VZV viruses requires an interprofessional team effort by healthcare professionals comprised of physicians, nurses, lab technicians, infectious disease specialists, pharmacists, and social workers. Such a team would be able to enhance the optimal outcomes&#x000a0;during&#x000a0;the administration of this drug. Prompt action in the diagnosis of infection and administration of the drug is fundamental to the optimal efficacy of this therapy.<xref ref-type="bibr" rid="article-21935.r28">[28]</xref></p>
        <p>Additionally, since this drug is not available orally and is administered most commonly via intravenous routes, it is of utmost importance to have the team involved with consistently monitoring the drug&#x02019;s effect on the patient&#x02019;s condition, especially during dosing changes.<xref ref-type="bibr" rid="article-21935.r29">[29]</xref>&#x000a0;Potential obstacles to ineffective therapy with foscarnet include inefficient interprofessional communication between team members, inconsistency in surveillance of the patient&#x02019;s progress with the treatment, or concurrent usage of drugs that may interfere with foscarnet therapy.<xref ref-type="bibr" rid="article-21935.r30">[30]</xref>&#x000a0;</p>
        <p>Compliance and overdose are&#x000a0;aspects of the medication that require emphasis&#x000a0;during patient education. The education should come from all team members, such as physicians, specialists, nurses, and pharmacists. Since appropriate dosing of this drug is very crucial,&#x000a0;clinicians must always be on the same page with the individualized aspect of therapy:&#x000a0;the patient&#x02019;s past medical history, inpatient and outpatient medication list, and changes in dosages of the foscarnet therapy regimen should always be available and consistent between all of them. With renal dysfunction being&#x000a0;a major concern&#x000a0;associated with&#x000a0;this drug, the interprofessional team needs to monitor renal function.<xref ref-type="bibr" rid="article-21935.r31">[31]</xref><xref ref-type="bibr" rid="article-21935.r18">[18]</xref>&#x000a0;Consultation with nephrology is recommended in cases of foscarnet overdose or nephrotoxicity.</p>
        <p>Upon completion of therapy, the patient&#x02019;s primary care physician or infectious disease physician must schedule follow-up visits to assess remission status versus recurrence; this is a crucial part of treatment as it catches any early recurrence of disease and prevents the need to reinitiate therapy (thereby exposing the patient to more adverse effects).&#x000a0;An interprofessional team approach and communication among clinicians are crucial to decreasing potential adverse effects, improving disease course, and improving patient outcomes&#x000a0;related&#x000a0;to foscarnet therapy.</p>
      </sec>
      <sec id="article-21935.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21935&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21935">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21935/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21935">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21935.s11">
        <title>References</title>
        <ref id="article-21935.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Razonable</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Antiviral drugs for viruses other than human immunodeficiency virus.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>86</volume>
            <issue>10</issue>
            <fpage>1009</fpage>
            <page-range>1009-26</page-range>
            <pub-id pub-id-type="pmid">21964179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piperi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Papadopoulou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Georgaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dovrat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bar Illan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nikitakis</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Yarom</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of oral herpes simplex virus infections: The problem of resistance. A narrative review.</article-title>
            <source>Oral Dis</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>877</fpage>
            <page-range>877-894</page-range>
            <pub-id pub-id-type="pmid">37279074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagstaff</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bryson</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.</article-title>
            <source>Drugs</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-226</page-range>
            <pub-id pub-id-type="pmid">7527325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sall&#x000e9;e</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boutolleau</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review.</article-title>
            <source>Rev Med Virol</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>e2574</fpage>
            <pub-id pub-id-type="pmid">39090526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Cytomegalovirus Treatment.</article-title>
            <source>Curr Treat Options Infect Dis</source>
            <year>2014</year>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>256</fpage>
            <page-range>256-270</page-range>
            <pub-id pub-id-type="pmid">25999800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vittayawacharin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>E'Leimat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Doh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blodget</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jeyakumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kongtim</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ciurea</surname>
                <given-names>SO</given-names>
              </name>
            </person-group>
            <article-title>Once-Daily Foscarnet Is Effective for Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell Transplantation.</article-title>
            <source>Transplant Cell Ther</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>397.e1</fpage>
            <page-range>397.e1-397.e6</page-range>
            <pub-id pub-id-type="pmid">36878429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norris</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bhavan</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Zurlo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hersh</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gorski</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bosso</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rathore</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Arrieta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petrak</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Umscheid</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e35</page-range>
            <pub-id pub-id-type="pmid">30423035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hakki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.</article-title>
            <source>Transpl Infect Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-3</page-range>
            <pub-id pub-id-type="pmid">24621186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Foscarnet</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31643840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Putera</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ridwan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Dewi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cifuentes-Gonz&#x000e1;lez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rojas-Carabali</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sitompul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edwar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Susiyanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aziza</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pavesio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Mahendradas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>de-la-Torre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>La Distia Nora</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2024</year>
            <season>Jan-Feb</season>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-84</page-range>
            <pub-id pub-id-type="pmid">37774799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaz-Llopis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espa&#x000f1;a</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Navea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chipont</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menezo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-4</page-range>
            <pub-id pub-id-type="pmid">8123619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chilukuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Management of acyclovir-resistant herpes simplex virus.</article-title>
            <source>Dermatol Clin</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-20</page-range>
            <pub-id pub-id-type="pmid">12757254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.</article-title>
            <source>Am J Med</source>
            <year>1992</year>
            <month>Feb</month>
            <day>14</day>
            <volume>92</volume>
            <issue>2A</issue>
            <fpage>26S</fpage>
            <page-range>26S-29S</page-range>
            <pub-id pub-id-type="pmid">1310573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammond</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Rangaraju</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sumner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Timmler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chandrasekar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>A Multicenter Assessment of the Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>ofae046</fpage>
            <pub-id pub-id-type="pmid">38444818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trifillis</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Drusano</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>2496</fpage>
            <page-range>2496-9</page-range>
            <pub-id pub-id-type="pmid">8285643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurice-Estepa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daudon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katlama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jouanneau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sazdovitch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lacour</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Beaufils</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Identification of crystals in kidneys of AIDS patients treated with foscarnet.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>392</fpage>
            <page-range>392-400</page-range>
            <pub-id pub-id-type="pmid">9740154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deffert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stoermann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ernandez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nabergoj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chalandon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jaeger</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury.</article-title>
            <source>Kidney Int Rep</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>11</issue>
            <fpage>2102</fpage>
            <page-range>2102-2108</page-range>
            <pub-id pub-id-type="pmid">33163731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Katlama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levaltier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Beaufils</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Danis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rozenheim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baumelou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dohin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gentilini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Foscarnet nephrotoxicity: mechanism, incidence and prevention.</article-title>
            <source>Am J Nephrol</source>
            <year>1989</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>316</fpage>
            <page-range>316-21</page-range>
            <pub-id pub-id-type="pmid">2554731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farese</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Schambelan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stringari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.</article-title>
            <source>Ann Intern Med</source>
            <year>1990</year>
            <month>Jun</month>
            <day>15</day>
            <volume>112</volume>
            <issue>12</issue>
            <fpage>955</fpage>
            <page-range>955-6</page-range>
            <pub-id pub-id-type="pmid">2160217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillaume</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Karmali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cogan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS.</article-title>
            <source>Clin Infect Dis</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>932</fpage>
            <page-range>932-3</page-range>
            <pub-id pub-id-type="pmid">9356819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayaweera</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Minimising the dosage-limiting toxicities of foscarnet induction therapy.</article-title>
            <source>Drug Saf</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>258</fpage>
            <page-range>258-66</page-range>
            <pub-id pub-id-type="pmid">9113493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2024</year>
            <month>Oct</month>
            <day>10</day>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">39377277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Moe</surname>
                <given-names>OW</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Metabolic Acidosis.</article-title>
            <source>F1000Res</source>
            <year>2015</year>
            <volume>4</volume>
            <pub-id pub-id-type="pmid">26918138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gearhart</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Sorg</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.</article-title>
            <source>Ann Pharmacother</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-9</page-range>
            <pub-id pub-id-type="pmid">8384030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ota</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Noto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hosomi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Relationship between serum calcium and&#x000a0;creatinine in hematopoietic stem cell transplantation patients treated with foscarnet&#x02029;.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>274</fpage>
            <page-range>274-281</page-range>
            <pub-id pub-id-type="pmid">32101522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Burney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Landman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Quale</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet.</article-title>
            <source>Clin Infect Dis</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>378</fpage>
            <pub-id pub-id-type="pmid">8838205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwan</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Acute kidney injury in a renal transplant recipient due to concomitant use of vancomycin and foscarnet.</article-title>
            <source>Nephrology (Carlton)</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>821</fpage>
            <page-range>821-822</page-range>
            <pub-id pub-id-type="pmid">28921753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ordemann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Geissler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kroschinsky</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bornh&#x000e4;user</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwerdtfeger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ehninger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?</article-title>
            <source>Ann Hematol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>79</volume>
            <issue>8</issue>
            <fpage>432</fpage>
            <page-range>432-6</page-range>
            <pub-id pub-id-type="pmid">10985362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mylonakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kallas</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.</article-title>
            <source>Clin Infect Dis</source>
            <year>2002</year>
            <month>May</month>
            <day>15</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1337</fpage>
            <page-range>1337-41</page-range>
            <pub-id pub-id-type="pmid">11981729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inose</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagayama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of the concomitant use of foscarnet and aerosolized pentamidine in allogeneic hematopoietic stem cell transplantation recipients.</article-title>
            <source>Transpl Infect Dis</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>e13239</fpage>
            <pub-id pub-id-type="pmid">31883423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21935.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierce</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lacloche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ison</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.</article-title>
            <source>Transpl Infect Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>e12852</fpage>
            <pub-id pub-id-type="pmid">29380479</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
